Mestag was founded in 2020 to develop new medicines for people affected by inflammatory disease and cancer. The company develops impactful therapies for patients by targeting activated fibroblast populations and determining their role in influencing the immune system in disease. Mestag’s founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology united in a common vision of the role of fibroblasts in disease: Professor Michael Brenner (Brigham and Women’s Hospital & Harvard Medical School), Professor Chris Buckley (Oxford Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School & Broad Institute) and Professor Mark Coles (Oxford Kennedy Institute, University of Oxford).
The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag is headquartered in Cambridge, UK. For more information, visit www.mestagtx.com
The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag is headquartered in Cambridge, UK. For more information, visit www.mestagtx.com
Location: United Kingdom, England, Cambridge
Total raised: $35.99M
Investors 1
| Date | Name | Website |
| - | Forbion | forbion.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 28.08.2024 | Grant | $1.98M | - |
| 04.08.2021 | Seed | $34.01M | Forbion |
Mentions in press and media 13
| Date | Title | Description |
| 08.10.2024 | Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases | – Exclusively deploys Mestag’s proprietary RAFT platform to interrogate the pathogenic role of fibroblasts in inflammatory disease for novel target discovery Cambridge, UK, October 8, 2024 – Mestag Therapeutics (“Mestag”), a biotech company... |
| 29.08.2024 | Biocon Biologics and Mestag Therapeutics: Pioneering Paths in Biosimilars and Cancer Treatment | In the world of biotechnology, innovation is the lifeblood. Two companies, Biocon Biologics and Mestag Therapeutics, are carving their niches in this dynamic landscape. Their recent developments signal a shift in how we approach treatment f... |
| 28.08.2024 | Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300 | – Innovate UK, part of UK Research and Innovation, is investing £12 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to Mestag – Bispecific antibody MST-0300 is a f... |
| 28.08.2024 | Mestag Therapeutics Receives £1.5M Grant from Innovate UK’s Cancer Therapeutics Program | Mestag Therapeutics, a Cambridge, MA-based biotech company harnessing new insights into fibroblast-immune interactions, received a £1.5M Grant from Innovate UK’s Cancer Therapeutics Program. The company intends to use the amount to accelera... |
| 05.03.2024 | Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting | - |
| 20.02.2024 | Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program | Cambridge, UK, February 20, 2024 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, today announced the appointments of additional di... |
| 12.10.2023 | Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA | Cambridge, UK, October 12, 2023 – Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful treatments for patients, today announced the appointment of expert advisors... |
| 27.06.2023 | Mestag Therapeutics and VIB enter into an exclusive partnership in oncology | Cambridge, UK, and Ghent, Belgium, June 27, 2023 – Mestag Therapeutics (‘Mestag’), an immunotherapy company focusing on fibroblast-immune interactions, and VIB, the leading life science research institute in Flanders, today announced enteri... |
| 20.12.2022 | Mestag Therapeutics appoints Prof. Ton Logtenberg as Chair | CAMBRIDGE, England, Dec. 20, 2022 /PRNewswire/ -- Mestag Therapeutics ("Mestag"), an immunotherapy company harnessing new insights into fibroblast-immune interactions in cancer and inflammatory disease, today announced the appoint... |
| 20.10.2022 | Mestag Therapeutics founding investigator Prof. David A. Tuveson elected to US National Academy of Medicine | Cambridge, UK, October 20, – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, is pleased to congratulate Prof. David A. Tuveson, one of its founding investigators, on his election to the US Na... |
Show more